News

Novartis9h
Novartis receives approval for first malaria medicine for newborn babies and young infants
Coartem® (artemether-lumefantrine) Baby becomes first malaria treatment approved for newborn babies and young infants Rapid approvals in eight African countries now expected under a special global ...
Novartis1d
Career Search | Novartis Slovenia
Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.
Novartis7d
Teresa Jose
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so ...
Novartis13d
Novartis completes acquisition of Regulus Therapeutics
We are excited to welcome the talented team at Regulus to Novartis as we continue to build on our pipeline in renal disease with high unmet medical need.” Farabursen is an investigational ...
Novartis2mon
Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure
Regulus is a clinical-stage biopharmaceutical company developing microRNA therapeutics with a focus on autosomal dominant polycystic kidney disease (ADPKD), a severe renal disease Lead asset for ADPKD ...
Novartis3mon
Novartis plans to expand its US-based manufacturing and R&D footprint with a total investment of $23B over the next 5 years
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities With new manufacturing capacity, Novartis will be able to produce 100% of its key ...
Novartis3mon
Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA ...
Vanrafia can be seamlessly added to supportive care in IgAN and used as a foundational therapy with no requirement for a REMS (Risk Evaluation Mitigation Strategy) program1 Phase III data showed ...
Novartis3mon
FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer
New indication approximately triples eligible patient population, allowing Pluvicto ® to be used after one androgen receptor pathway inhibitor (ARPI) and now before chemotherapy Pluvicto significantly ...
Novartis3mon
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)
EAST HANOVER, N.J., March 20, 2025 -- Novartis today announced that oral Fabhalta ® (iptacopan) has received U.S. Food and Drug Administration (FDA) approval for the treatment of adults with C3 ...
Novartis3mon
New Novartis Phase III data demonstrate meaningful efficacy and safety results of intrathecal onasemnogene abeparvovec in broad patient population with SMA
Basel, March 19, 2025 – Novartis announced positive safety and efficacy results from the Phase III program for investigational intrathecal onasemnogene abeparvovec (OAV101 IT) in a broad population of ...
Novartis7mon
Addressing unmet needs for inherited neuromuscular diseases
Novartis has acquired Kate Therapeutics to further enhance and strengthen our ongoing efforts to advance gene therapies for patients.
Novartis11mon
Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)
Basel, August 8, 2024 – Novartis today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Fabhalta ® (iptacopan), a first-in-class complement inhibitor for ...